Evidence map›Paper›PMID 41503493›Full record

ReviewRSC advances2026

Upconversion materials: a new frontier in solar water-splitting.

Yerbolat Magazov, Asset Aliyev, Nursaya Zhumabay, Zhamilya Taubaldiyeva, Guldana Zhigerbayeva, Nurxat Nuraje

Abstract readReview
In one paragraph

Review in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yerbolat MagazovRenewable Energy Lab, National Laboratory Astana Astana 010000 Kazakhstan guldana.zhigerbaeva@nu.edu.kz nurxat.nuraje@nu.edu.kz.ORCID https://orcid.org/0000-0002-0902-3140
Asset AliyevRenewable Energy Lab, National Laboratory Astana Astana 010000 Kazakhstan guldana.zhigerbaeva@nu.edu.kz nurxat.nuraje@nu.edu.kz.ORCID https://orcid.org/0009-0008-2471-3757
Nursaya ZhumabayRenewable Energy Lab, National Laboratory Astana Astana 010000 Kazakhstan guldana.zhigerbaeva@nu.edu.kz nurxat.nuraje@nu.edu.kz.
Zhamilya TaubaldiyevaDepartment of Chemical and Materials Engineering, Nazarbayev University Astana 010000 Kazakhstan.
Guldana ZhigerbayevaRenewable Energy Lab, National Laboratory Astana Astana 010000 Kazakhstan guldana.zhigerbaeva@nu.edu.kz nurxat.nuraje@nu.edu.kz.ORCID https://orcid.org/0000-0001-8556-4865
Nurxat NurajeRenewable Energy Lab, National Laboratory Astana Astana 010000 Kazakhstan guldana.zhigerbaeva@nu.edu.kz nurxat.nuraje@nu.edu.kz.ORCID https://orcid.org/0000-0002-4335-8905

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Limited utilization of the solar spectrum is a major bottleneck in photocatalytic water-splitting, as most semiconductor photocatalysts only harness UV or visible light, leaving a large fraction of infrared photons unused. Upconversion materials have emerged as a promising solution by converting two or more low-energy photons into a single higher-energy photon, thereby extending the photoresponse of water-splitting systems. This review provides a technical overview of the two leading upconversion strategies for solar hydrogen generation: lanthanide (Ln)-based upconversion phosphors and triplet-triplet annihilation (TTA) upconversion systems, including purely organic and metal-organic approaches. We discuss how Ln-doped upconverters can enable near-infrared-driven photocatalysis, while highlighting their efficiency limitations under 1-sun illumination. We then examine TTA-based upconversion, which leverages molecular sensitizer-emitter pairs to achieve efficient upconversion under solar light intensities, and summarize recent demonstrations of TTA systems boosting H

Identifiers

PMID41503493
PMCPMC12771292

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.